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MicroRNAs (miRNAs) play pivotal roles in numerous biological processes, and their
dysregulation is a common feature of human cancer. Thanks to recent advances in the
analysis of the cancer epigenome, we now know that epigenetic alterations, including
aberrant DNA methylation and histone modiﬁcations, are major causes of miRNA
dysregulation in cancer. Moreover, the list of miRNA genes silenced in association with
CpG island hypermethylation is rapidly growing, and various oncogenic miRNAs are now
known to be upregulated via DNA hypomethylation. Histone modiﬁcations also play
important roles in the dysregulation of miRNAs, and histone deacetylation and gain of
repressive histone marks are strongly associated with miRNA gene silencing. Conversely,
miRNA dysregulation is causally related to epigenetic alterations in cancer. Thus aberrant
methylation of miRNA genes is a potentially useful biomarker for detecting cancer and
predicting its outcome. Given that many of the silenced miRNAs appear to act as tumor
suppressors through the targeting of oncogenes, re-expression of the miRNAs could
be an effective approach to cancer therapy, and unraveling the relationship between
epigenetic alteration andmiRNAdysregulationmay lead to the discovery of new therapeutic
targets.
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INTRODUCTION
MicroRNAs (miRNAs) are endogenous, small, non-coding single-
stranded RNAs about 22 nucleotides in length, which function
at the post-transcriptional level as negative regulators of gene
expression (He and Hannon, 2004). Each miRNA negatively reg-
ulates its target genes in one of two ways, depending on the
degree of complementarity between itself and its target messenger
RNAs (mRNAs). miRNAs that bind tomRNA sequences with per-
fect or nearly perfect complementarity induce the RNA-mediated
interference (RNAi) pathway, in which mRNA transcripts are
cleaved by a miRNA-associated RNA-induced silencing complex
(miRISC). This mechanism is mainly observed in plants, though
miRNA-directed mRNA cleavage does occur in animals. Most
animal miRNAs are thought to act by binding to imperfectly
complementary sites within the 3′ untranslated regions (UTRs)
of target mRNAs, thus inhibiting the initiation of translation via
the miRISC.
Annotation of their genomic locations suggests that many
miRNA genes are located within intergenic regions, though they
are also found within exonic and intronic regions in either the
sense or antisense orientation. Like genes encoding proteins,
miRNA genes are mainly transcribed by RNA polymerase II. They
are initially transcribed as large precursors, called primary miR-
NAs (pri-miRNAs), which may encode multiple miRNAs in a
polycistronic arrangement. Pri-miRNAs are then processed by
the RNase III enzyme Drosha and its cofactor DGCR8/Pasha to
produce∼70-nt hairpin-structured second precursors, called pre-
miRNAs. The pre-miRNAs are transported to the cytoplasm by
the nuclear export protein Exportin-5 (XPO5), after which they
are processed by another RNase III enzyme, DICER, to generate
mature miRNA products.
Sequences of miRNAs are highly conserved among species, and
play critical roles in a variety of biological processes, including
cell proliferation, development, differentiation, and apoptosis.
In addition, subsets of miRNAs are thought to act as tumor
suppressor genes or oncogenes, and their dysregulation is a com-
mon feature of human cancers (Esquela-Kerscher and Slack,
2006; Croce, 2009). More speciﬁcally, expression of miRNAs
is generally downregulated in tumor tissues, as compared to
corresponding healthy tissues, which suggests some miRNAs
behave as tumor suppressors in some tumors. Although the
mechanism underlying the alteration of miRNA expression in
cancer is still not fully understood, recent studies have shown
that cancer affects multiple mechanisms involved in regulating
miRNA levels. For example, a signiﬁcant number of miRNAs
are located within cancer-associated genomic regions or in frag-
ile sites (Calin et al., 2004). The ﬁrst report of altered miRNA
expression in cancer was related to the frequent chromosomal
deletion and downregulated expression of miR-15 and miR-16,
two miRNAs thought to target the antiapoptotic factor B cell
lymphoma 2 (BCL2) in chronic lymphocytic leukemia (CLL;
Calin et al., 2002). More recent studies indicate that genetic
mutations affecting proteins involved in the processing and mat-
uration of miRNA, such as TARBP2 and XPO5, can also lead
to overall reductions in miRNA expression (Melo et al., 2009,
2010). In addition, epigenetic alterations, including aberrant DNA
methylation and histone modiﬁcations, appear to be a major
mechanism by which the normal patterns of miRNA expression
are disrupted in cancer. In this review, we will highlight the con-
tribution made by epigenetic alteration of miRNAs to cancer, and
discuss their clinical application as biomarkers and therapeutic
targets.
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IDENTIFICATION OF EPIGENETICALLY DYSREGULATED
miRNAs IN CANCER
The ﬁrst evidence that epigenetic mechanisms are involved
in silencing miRNAs in cancer came from a pharmacologi-
cal unmasking experiment. Using a miRNA microarray, Saito
et al. (2006) analyzed the expression proﬁles of miRNAs in
T24 human bladder cancer cells and LD419 human normal
ﬁbroblasts treated with or without the DNA methyltransferase
(DNMT) inhibitor 5-aza-2′-deoxycytidine (5-aza-dC) and the
histone deacetylase (HDAC) inhibitor 4-phenylbutyric acid (4-
PBA). Among the genes upregulated in the cancer cells was
miR-127, which was embedded within a CpG island and was
upregulated in association with DNA demethylation, acetyla-
tion of histone H3 and trimethylation of histone H3 lysine 4
(H3K4me3), which are marks of active transcription. Exper-
imental evidence conﬁrmed that the proto-oncogene BCL6 is
a target of miR-127, suggesting miR-127 acts as a tumor
suppressor (Saito et al., 2006).
As with protein-coding genes, epigenetic regulation of miRNA
genes is tightly associated with histone modiﬁcation (Figure 1).
As mentioned, H3K4me3 and acetylation of histone H3 lysine
9/14 are hallmarks of active miRNA gene promoters in embry-
onic stem cells and in cancer cells (Marson et al., 2008; Ozsolak
et al., 2008; Suzuki et al., 2011). By contrast, di- or trimethy-
lation of histone H3 lysine 9 (H3K9me2 or H3K9me3) and
trimethylation of lysine 27 (H3K27me3) are marks of repres-
sion. For instance, a combination of chromatin immunopre-
cipitation (ChIP)-on-chip and miRNA microarray analyses in
prostate cancer cells revealed that miRNA expression correlates
positively withH3K4me3 and correlates inversely withH3K27me3
in miRNA promoter regions (Ke et al., 2009). In addition,
genome-wide screening for miRNA genes with reduced lev-
els of H3K4me3 and increased levels of H3K9me2 led to
the identiﬁcation of 13 miRNA genes, including the miR-124
family, miR-9 family, and miR-34b/c, that are epigenetically
silenced in acute lymphoblastic leukemia (ALL; Roman-Gomez
et al., 2009). To assess genome-wide histone modiﬁcations, we
recently performed deep sequencing (ChIP-seq) in colorectal can-
cer (CRC) cells and identiﬁed the putative promoter regions
of 174 pri-miRNA genes (Suzuki et al., 2011). By searching for
miRNAs that showed upregulated expression and increases in
H3K4me3 marks upon DNA demethylation, we identiﬁed 37
miRNA genes as potential targets of epigenetic silencing in CRC
cells.
Epigenetically silenced miRNA genes were also identiﬁed
through genome-wide DNA methylation analysis. For instance,
methylation microarray analysis using the Inﬁnium BeadChip
revealed miR-10b to be a target of DNA methylation in gas-
tric cancer (GC; Kim et al., 2011). In addition, Yan et al. (2011)
performed a genome-wide methylome analysis entailing deep
sequencing of MBD (methylated DNA binding domain)-isolated
DNA in HCT116 cells, and identiﬁed a number of methylated
genes, including miR-941, miR-1237, and miR-1247. And Baer
et al. (2012) carried out an integrative analysis of genome-wide
DNA methylation and histone modiﬁcation (H3K4me3) in CLL
and identiﬁed 128 miRNAs that carried aberrant DNA methy-
lation at their promoters. Interestingly, of those 128 miRNA
promoters, 38 exhibited hypermethylation, while 90 showed
hypomethylation, which are indicative of epigenetically silenced
and activated miRNAs, respectively. In fact, the hypermethylated
FIGURE 1 | Epigenetic silencing of miRNA genes in cancer. Example
of a miRNA gene with its CpG island. In normal cells, the CpG island
is unmethylated, and the chromatin is associated with active histone
modiﬁcations. In cancer cells, CpG island hypermethylation and
repressive histone marks lead to epigenetic silencing of the miRNA
gene (left). Alternatively, some miRNA genes are silenced through
repressive histone modiﬁcations, rather than DNA methylation
(right).
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regions included a number of well-deﬁned epigenetically silenced
miRNA genes, including miR-9-2, miR-124-2, and miR-129-
2, while the hypomethylation was accompanied by upregu-
lation of several miRNAs, including miR-21, miR-34a, and
miR-155.
ABERRANT DNA METHYLATION OF miRNA GENES IN
CANCER
Among the rapidly growing list of miRNAs that are now known
to be aberrantly methylated in cancer, many are downregulated
in association with CpG island hypermethylation, while some are
upregulated via hypomethylation of their CpG island. Here we
describe well-characterized miRNA genes showing aberrant DNA
methylation in cancer.
Epigenetic silencing of miR-124 family genes was ﬁrst discov-
ered in CRC (Lujambio et al., 2007), and they are now known
to be methylated in several other types of malignancy, including
ALL (Agirre et al., 2009), non-Hodgkin’s lymphoma (Wong et al.,
2011a), and liver (Furuta et al., 2010), pancreatic (Wang et al.,
2013), renal (Gebauer et al., 2013), and cervical cancer (Wilting
et al., 2010). Within the human genome, three independent loci
(miR-124-1, miR-124-2, and miR-124-3) encode identical mature
forms of miR-124, and all are associated with CpG islands, which
may be targets of hypermethylation in cancer (Lujambio et al.,
2007). miR-124 exerts its tumor suppressor function by targeting
cyclin-dependent kinase 6 (CDK6), and epigenetic silencing of
miR-124 reportedly results inCDK6activation andRbphosphory-
lation (Lujambio et al., 2007; Agirre et al., 2009). In ALL, miR-124
methylation is associated with higher recurrence and mortality
rates, andmaybe an independent prognostic factor for disease-free
and overall survival (Agirre et al., 2009). miR-124 family genes are
also frequently methylated in the gastric mucosa of Helicobacter
pylori-positive healthy individuals, suggesting their methylation
could be induced by chronic inﬂammation (Ando et al., 2009).
Members of the miR-34 gene family (miR-34a, miR-34b, and
miR-34c) are direct targets of p53, and their ectopic expression
in cancer cells induces cell cycle arrest and apoptosis (Bommer
et al., 2007; He et al., 2007). Within the human genome, miR-
34a is located on chromosome 1p36, while miR-34b and miR-34c
are co-transcribed from a single transcription unit on chromo-
some 11q23. The promoters of both genes are targets of CpG
island hypermethylation in multiple malignancies including oral
(Kozaki et al., 2008), esophageal (Chen et al., 2012), gastric (Suzuki
et al., 2010), colorectal (Toyota et al., 2008), lung (Wang et al.,
2011b), breast and renal cancer (Lodygin et al., 2008; Vogt et al.,
2011), and hematological malignancies (Roman-Gomez et al.,
2009; Wong et al., 2011b). Methylation of miR-34b/c has also
been linked to cancer metastasis (Lujambio et al., 2008) and inva-
sion (Watanabe et al., 2012). In addition, methylation-associated
silencing of miR-34c was recently shown to promote self-renewal
and epithelial–mesenchymal transition (EMT) in breast tumor-
initiating cells (Yu et al., 2012). These ﬁndings, as well as their
contribution to the p53 network, strongly imply that miR-34 fam-
ily members act as tumor suppressors in cancer. Introduction of
miR-34b/c into cancer cells leads to the downregulation of can-
didate target genes, including MET, CDK4, cyclin E2 (CCNE2),
and MYC (Lujambio et al., 2008; Toyota et al., 2008). Likewise,
restoration of endogenous miRNA expression through demethy-
lation also downregulates target genes, suggesting miRNAs could
be important targets for epigenetic cancer therapy (Toyota et al.,
2008).
The CpG islands of miR-9 family genes (miR-9-1, miR-9-2,
and miR-9-3) are also frequently methylated in various types of
malignancies, including ALL (Roman-Gomez et al., 2009) and
colorectal (Bandres et al., 2009), breast (Lehmann et al., 2008),
pancreatic (Omura et al., 2008), and GCs (Tsai et al., 2011). More-
over, a screen formiRNAgenemethylation inmetastatic cancer cell
lines identiﬁedmiR-9 family genes as beingmethylated (Lujambio
et al., 2008). Consistent with that ﬁnding, methylation of miR-
9-1 is reportedly associated with lymph node metastasis in CRC
(Bandres et al., 2009), while methylation of miR-9-1 and miR-
9-3 correlates with metastatic recurrence of renal cell carci-
noma (Hildebrandt et al., 2010). miR-9 has been shown to
target ﬁbroblast growth factor receptor 1 (FGFR1) and CDK6
in ALL (Rodriguez-Otero et al., 2011) and caudal-type home-
obox 2 (CDX2) in GC (Rotkrua et al., 2011), suggesting a
tumor-suppressive function.
The miR-200 gene family (miR-200a, miR-200b, miR-200c,
miR-141, and miR-429) and miR-205 encode key regulators of
EMT that act by directly targeting zinc ﬁnger E-box binding
homeobox 1 (ZEB1) and ZEB2, which are transcriptional repres-
sors that downregulate E-cadherin (CDH1; Gregory et al., 2008;
Korpal et al., 2008; Park et al., 2008). Within the human genome,
miR-200 family genes are grouped into two polycistronic units,
miR-200b/200a/429 and miR-200c/141, located on chromosomes
1 and 12, respectively (Davalos et al., 2012). In normal mam-
mary epithelial cells and ﬁbroblasts, expression of miR-200 family
and miR-205 genes is regulated by DNA methylation, histone
modiﬁcations, or a combination of the two (Vrba et al., 2010),
but aberrant DNA methylation leads to the silencing of these
miRNAs in cancer (Ceppi et al., 2010; Neves et al., 2010; Wik-
lund et al., 2011). For instance, methylation of miR-200c/141
is tightly correlated with the invasive capacity of breast cancer
cells (Neves et al., 2010). Similarly, in non-small cell lung cancer,
promoter methylation is associated with loss of miR-200c expres-
sion, which is in turn associated with poor differentiation, lymph
node metastasis, and weaker E-cadherin expression (Ceppi et al.,
2010). Davalos et al. (2012) demonstrated that the upstream CpG
islands of both units (miR-200b/200a/429 and miR-200c/141) are
unmethylated in cancer cells with epithelial features, but are both
methylated and silenced in transformed cells with mesenchymal
characteristics.
In addition to its therapeutic implications,miRNAgenemethy-
lation could be a useful molecular marker for detecting cancer
and/or predicting its outcome. For instance, the CpG island of
miR-34b/c is methylated in more than 90% of primary CRCs,
and methylation was detected in 75% of fecal specimens from
CRC patients and in 16% of specimens from high-grade dyspla-
sia patients, suggesting miR-34b/c methylation could be a useful
feces-based screening marker (Kalimutho et al., 2011). It was also
recently shown thatmiR-34amethylation andhigh levels of c-MET
and β-catenin expression may be powerful predictive markers of
liver metastasis in CRC (Siemens et al., 2013). In addition, miR-
34b/c methylation was found to be elevated in the background
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gastric mucosa of multiple GC patients (Suzuki et al., 2010), and
a subsequent study revealed that miR-34b/c methylation could
be a marker for predicting the risk of metachronous GC (Suzuki
et al., 2013). miRNA gene methylation is also detectable in urine
specimens, and could be a useful marker of urinary tract cancer.
A recent screening for epigenetically silenced miRNAs in bladder
cancer cells identiﬁed methylation of four miRNA genes (miR-
137, miR-124-2, miR-124-3, and miR-9-3), and their methylation
in urinary DNA was found to be a useful biomarker of bladder
cancer (Shimizu et al., 2013).
Many miRNA genes are reportedly downregulated in asso-
ciation with DNA hypermethylation in cancer, but some are
epigenetically activated via DNA hypomethylation. Asmentioned,
a recent comprehensive analysis of miRNA in CLL revealed that
approximately 60% of aberrantly methylatedmiRNA genes exhib-
ited hypomethylation (Baer et al., 2012). For instance, the CpG
island of let-7a-3 is heavily methylated in normal cells but is
hypomethylated in lung adenocarcinoma, leading to its elevated
expression (Brueckner et al., 2007). In lung cancer cells, let-7a-3
exerts oncogenic effects through actions on several genes involved
in cell proliferation, adhesion, and differentiation. In addition,
miR-200a and miR-200b are overexpressed in pancreatic cancer
due to their hypomethylation, and their elevation in the serum
of pancreatic cancer patients means they could potentially serve
as diagnostic biomarkers (Li et al., 2010). miR-196 family genes
(miR-196a and miR-196b) are located within the HOX gene clus-
ter and are often overexpressed in tumors, which is indicative of
their oncogenic functions (Luthra et al., 2008; Maru et al., 2009;
Popovic et al., 2009; Guan et al., 2010). miR-196b is embedded
within a CpG island, and its overexpression in GC is associated
with its hypomethylation (Tsai et al., 2010).
Recently, Fornari et al. (2012) reported that miR-519d is upreg-
ulated due to DNA hypomethylation in hepatocellular carcinoma
(HCC). miR-519d belongs to the chromosome 19 miRNA clus-
ter (C19MC), which is the largest miRNA cluster in the human
genome. miRNAs in the C19MC are normally expressed speciﬁ-
cally in placenta (Bentwich et al., 2005), but DNA demethylation
leads to their re-expression in cancer cells, which is indicative
of their epigenetic repression in healthy tissue (Tsai et al., 2009;
Suzuki et al., 2011). Upregulation of miR-519d, which is observed
in approximately 50% of HCCs, is positively associated with CpG
island hypomethylation and wild-type p53 (Fornari et al., 2012).
miR-519d is thought to act as an oncogenic miRNA (oncomir)
through its targeting of p21, PTEN, AKT3, and TIMP2.
miRNA DYSREGULATION CAUSES ABERRANT DNA
METHYLATION
Several lines of evidence support the idea that dysregulation of
miRNAs can lead to aberrant DNA methylation in cancer. For
instance, the miR-29 family (miR-29a, miR-29b, and miR-29c),
which is downregulated in lung cancer, directly targets DNMT3A
and DNMT3B (Fabbri et al., 2007; Figure 2). Ectopic expression
of the miR-29 family in lung cancer cells restores expression of
methylation-silenced tumor suppressor genes, including fragile
histidine triad (FHIT) and WW domain containing oxidoreduc-
tase (WWOX). In addition, miR-143 is frequently downregulated
in CRC cells, where it normally targets DNMT3A (Ng et al.,
FIGURE 2 | Dysregulation of miRNAs is causally related to epigenetic
alterations in cancer. miRNAs able to negatively regulate DNMTs or
EZH2 are frequently downregulated in cancer, which leads to epigenetic
silencing of target genes.
2009), and downregulated expression of miR-152 in HBV-related
HCC correlates with increased expression of DNMT1 (Huang
et al., 2010). Forced expression of miR-152 in liver cell lines
reducesDNMT1expression and globalDNAmethylation,whereas
inhibition of miR-152 causes global DNA hypermethylation
and increased methylation of the glutathione S-transferase pi 1
(GSTP1) and CDH1 promoter regions. Similarly, DNMT1 is tar-
geted by miR-148a and miR-152 in cholangiocarcinoma cells, and
their ectopic expression suppresses DNMT1 and induces expres-
sion of the tumor suppressor genes Ras association domain family
1A (RASSF1A) and p16 (Braconi et al., 2010). miR-342 was found
to be downregulated in CRC cells, and restoration of its expression
downregulated DNMT1 and reactivated expression of cancer-
related genes through demethylation of their promoter regions
(Wang et al., 2011a). miR-185 is downregulated in glioma cells in
association with loss of heterozygosity (LOH), and its restoration
reduces global DNA methylation and leads to re-expression of
hypermethylated genes through targeting DNMT1 (Zhang et al.,
2011b).
miR-34b was recently shown to target both DNMTs and
HDACs in prostate cancer cells (Majid et al., 2013). As in
other malignancies, miR-34b is silenced in association with
CpG island methylation in prostate cancer, and low miR-34b
expression is strongly associated with poor survival. Interest-
ingly, ectopic expression of miR-34b in prostate cancer cells
suppressed DNMTs and HDACs and induced partial demethy-
lation and active chromatin modiﬁcation of the endogenous
miR-34b gene, which suggests a positive feedback loop. Collec-
tively, these results indicate that dysregulation of speciﬁc miRNAs
may be causally related to aberrant methylation of promoter CpG
islands.
HISTONE MODIFICATIONS AND miRNA DYSREGULATION
It is now evident that histone modiﬁcations also play a major role
in the dysregulation of miRNAs in cancer. For example, treating a
breast cancer cell line with the HDAC inhibitor LAQ824 induced
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upregulation or downregulation of a number of miRNAswithin as
little 5 h (Scott et al., 2006). Not only does this suggest the involve-
ment of epigenetic mechanisms in the regulation of miRNAs in
cancer cells, it also highlights the importance of secondary effects
driven by miRNAs induced or downregulated through drug treat-
ment. In addition, recent studies have shown that HDAC silences
tumor-suppressive miRNAs in cancer. It is well documented that
loss of miR-15a and miR-16 in CLL is associated with 13q loss;
however, these miRNAs are also often downregulated in CLL
samples without observable deletions in 13q, and Sampath et al.
(2012) found that overexpression of HDACs (HDAC1, HDAC2,
and HDAC3) is associated with downregulation of miR-15a, miR-
16, and miR-29b. Furthermore, inhibition of the HDACs induced
robust accumulation of active histone marks at the promoters of
the miRNAs and increased their expression, which in turn led to
downregulation of their target genes, BCL2 andMCL1. In another
study, MYC interacted with HDAC3, which then colocalized to
the promoters of miR-15a/miR-16-1 and their host gene DLEU2,
resulting inMYC-induced suppression of thesemiRNAs inmantle
cell lymphoma (Zhang et al., 2012a). And inHCC,upregulation of
HDACs (HDAC1–3) was associated with repression of miR-449,
which led to activation of the putative miR-449 target gene c-MET
(Buurman et al., 2012).
In other settings, histone acetylation is involved in the activa-
tion of oncomirs in cancer. For example, miR-224 is commonly
upregulated in HCC, and there is reportedly a positive correla-
tion between miR-224 expression and histone acetylase protein
EP300 in HCC tumors (Wang et al., 2012). It is well documented
that the breast cancer susceptibility gene BRCA1 is involved in
DNA damage repair and cell cycle regulation, but a recent study
revealed an interesting link between BRCA1 and the epigenetic
regulation of oncomirs. Chang et al. (2011) showed that wild-type
BRCA1 epigenetically represses miR-155 by recruiting HDAC2 to
the miR-155 promoter, while a BRCA1 R1699Q mutant relieves
the repression and causes miR-155 to be overexpressed.
As mentioned, miRNA gene transcription is closely associ-
ated with histone modiﬁcations; thus some miRNA genes are
silencedwithoutDNAhypermethylation in cancer cells (Figure 1).
For example, downregulation of miR-212 in lung cancer cells
is reportedly associated with H3K9me2 and H3K27me3 but not
DNA hypermethylation (Incoronato et al., 2011; Figure 1). miR-
212 exerts a pro-apoptotic effect in lung cancer cells by targeting
the anti-apoptotic gene PED, and inhibition of HDAC and the
histone methyltransferase EZH2 strongly reactivates miR-212
expression in lung cancer cells. It was also recently found that
miR-708 is repressed by H3K27me3 in metastatic breast can-
cer (Ryu et al., 2013). miR-708 targets neuronatin (NNAT), a
regulator of intracellular Ca2+, and silencing miR-708 leads to
elevation of intracellular Ca2+ levels and increased cell migration
and metastasis.
miRNA DYSREGULATION CAUSES ABERRANT HISTONE
MODIFICATIONS
Dysregulation of miRNAs can also lead to aberrant histone mod-
iﬁcations. EZH2 is a member of the polycomb group (PcG) of
proteins, which are key regulators that silence numerous develop-
mental genes (Schuettengruber et al., 2007). EZH2 functions as a
catalytic subunit of polycomb repressive complex 2 (PRC2), which
trimethylates H3K27. The available evidence suggests that EZH2
has oncogenic properties, and its overexpression in prostate and
breast cancers promotes tumorigenesis, invasiveness and metas-
tasis (Varambally et al., 2002; Kleer et al., 2003). Varambally et al.
(2008) reported that EZH2 is a target of miR-101, and genomic
loss of miR-101 is an important cause of EZH2 overexpression
in cancer. Reduced expression of miR-101 and upregulation of
EZH2 occur in parallel during the progression of prostate can-
cer, and genomic loss of miR-101 is more frequently seen in
metastatic disease than localized cancers. Moreover, the loss of
miR-101 and resultant overexpression of EZH2 appears to alter
the global chromatin structure in cancer (Friedman et al., 2009).
The inverse association betweenmiR-101 and EZH2 has now been
seen in bladder, gastric, lung, and renal cancer (Friedman et al.,
2009; Wang et al., 2010; Zhang et al., 2011a; Sakurai et al., 2012).
In addition, several other miRNAs, including miR-26a (Wong and
Tellam, 2008), miR-98 (Alajez et al., 2010), miR-124 (Zheng et al.,
2012), miR-144 (Guo et al., 2013), miR-214 (Derfoul et al., 2011),
and let-7 (Kong et al., 2012) are also reported to negatively regulate
EZH2 (Figure 2). Thus, dysregulation of miRNAs appears to be
one of the major causes of EZH2 overexpression in cancer.
Overexpression of EZH2 also leads to the silencing of multi-
ple miRNAs in cancer. It was recently demonstrated that EZH2 is
frequently upregulated in primary HCCs, and miRNA expression
proﬁling inHCCcellswithEZH2-knockdown revealed that a set of
miRNAs, including miR-139-5p, miR-125b, let-7c, miR-101, and
miR-200b, are epigenetically suppressed by EZH2 in HCC (Au
et al., 2012). Interestingly, miR-200b reportedly targets another
PRC2 subunit, SUZ12, in breast cancer stem cells (Iliopoulos
et al., 2010), suggesting a possible feedback loop between EZH2
overexpression and miRNA silencing in cancer. In another study,
Cao et al. (2011) demonstrated that in prostate and breast cancer
cell lines, EZH2 represses a set of miRNAs (miR-181c, miR-181b,
miR-200b, miR-200c, and miR-203), which in turn negatively reg-
ulate the PRC1 subcomponents BMI1 and RING2. The inverse
correlation between miRNA and PRC protein levels were further
conﬁrmed in prostate cancer tissues. These results are indicative
of an integral regulatory axis involving PRC1, PRC2, and the
epigenetic silencing of miRNAs in cancer.
Another recent study demonstrated the involvement of EZH2
and HDAC3 in MYC-mediated miRNA repression. In aggressive
B cell lymphoma, miR-29a is repressed by MYC within a co-
repressor complex that also includes HDAC3 and EZH2 (Zhang
et al., 2012b). Interestingly, MYC contributes to EZH2 upregula-
tion through repression of miR-26a, which targets EZH2, while
EZH2 upregulates MYC by inhibiting miR-494, which targets
MYC. It thus appears a positive MYC-miRNA-EZH2 feedback
loop may mediate persistent overexpression of MYC and EZH2.
Combined inhibition of HDAC3 and EZH2 induced restoration
of miR-29 and suppressed lymphoma cell growth, suggesting
the MYC–EZH2–miRNA axis could be a promising target for
epigenetic therapy in B cell lymphoma.
CONCLUDING REMARKS
In this review, we highlighted the relationship between epigenetic
alteration of miRNAs and cancer. Aberrant DNA methylation
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commonly underlies miRNA dysregulation in cancer, and methy-
lation of a subset of miRNA genes may be a useful biomarker for
detecting cancer and/or predicting clinical outcome. Alteration of
the histone modiﬁcation pattern also leads to abnormal miRNA
expression. In addition, recent ﬁndings suggest that miRNA
dysregulation is causally related to aberrant DNA methylation
and histone modiﬁcations that leads to genome-wide epigenetic
abnormalities. It is anticipated that additional study of the rela-
tionship between epigenetic regulation and miRNAs will lead to
the discovery of new biomarkers as well as therapeutic targets.
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